Thrivent Financial for Lutherans Reduces Stock Holdings in Vaxcyte, Inc. $PCVX

Thrivent Financial for Lutherans lowered its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 67.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,184 shares of the company’s stock after selling 15,205 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Vaxcyte were worth $259,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PCVX. Edgestream Partners L.P. bought a new position in shares of Vaxcyte during the second quarter valued at approximately $1,610,000. Federated Hermes Inc. boosted its holdings in Vaxcyte by 6,856.3% during the 3rd quarter. Federated Hermes Inc. now owns 18,156 shares of the company’s stock valued at $654,000 after acquiring an additional 17,895 shares during the period. State of New Jersey Common Pension Fund D boosted its holdings in Vaxcyte by 36.4% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 55,477 shares of the company’s stock valued at $1,804,000 after acquiring an additional 14,799 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Vaxcyte in the 3rd quarter valued at $2,640,000. Finally, Quadrature Capital Ltd purchased a new stake in Vaxcyte in the second quarter worth $1,359,000. 96.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Needham & Company LLC boosted their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, January 9th. Guggenheim reissued a “buy” rating and issued a $116.00 price objective on shares of Vaxcyte in a research report on Monday, February 2nd. Leerink Partners set a $77.00 target price on shares of Vaxcyte and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Finally, BTIG Research reaffirmed a “buy” rating and set a $85.00 price target on shares of Vaxcyte in a research note on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Vaxcyte presently has an average rating of “Moderate Buy” and an average price target of $93.83.

Insiders Place Their Bets

In related news, SVP Elvia Cowan sold 11,623 shares of the company’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total transaction of $556,974.16. Following the completion of the sale, the senior vice president directly owned 14,534 shares in the company, valued at $696,469.28. This represents a 44.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of Vaxcyte stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total value of $454,900.67. Following the completion of the transaction, the insider owned 23,928 shares in the company, valued at $1,117,198.32. This trade represents a 28.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 3.10% of the company’s stock.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $56.17 on Thursday. The company has a market cap of $7.35 billion, a PE ratio of -11.61 and a beta of 1.33. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $84.10. The firm’s 50 day moving average price is $49.52 and its 200-day moving average price is $42.61.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.